Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice
- 5.3k Downloads
Topical calcineurin inhibitors (TCIs), commercially available since 2000–2001, are the first and only topical medications approved for chronic treatment of atopic dermatitis (AD) in pediatric patients and remain a welcomed alternative to topical corticosteroids. In January 2006, the US Food and Drug Administration (FDA) issued a boxed warning requirement based on a theoretical risk of malignancy (including lymphoma) with TCI use. However, in the years since, analyses of epidemiologic and clinical data have failed to demonstrate a causal relationship between TCI use and malignancy or lymphoma risk, especially for pimecrolimus cream. In fact, the observed number of malignancies and lymphomas observed both in post-marketing surveillance and reported to the FDA using its adverse events reporting system is much lower among TCI-exposed patients than the expected number for the general population. Furthermore, among children enrolled in post-marketing pediatric registry studies for both tacrolimus and pimecrolimus followed for up to 5.5 years [10,724 patient-years (PY)] or 6.5 years (16,219 PY), respectively, the observed number of malignancies and lymphomas is very low and similar to the number expected for a sample of similar size in the general population. In addition to reporting these comparative malignancy and lymphoma data, this article provides a historical overview of the boxed warning requirement and critically evaluates the preclinical, clinical, and epidemiological evidence that has thus far failed to substantiate a relationship between TCI use and malignancy. The authors also provide practical clinical advice for optimizing AD management and patient care in the context of the boxed warning.
KeywordsTacrolimus Atopic Dermatitis Pimecrolimus Boxed Warning Adverse Event Reporting System
Topical tacrolimus ointment and pimecrolimus cream have been commercially available for more than a decade and are the first and only drugs approved for chronic treatment of atopic dermatitis (AD) in pediatric patients. These topical calcineurin inhibitors (TCIs) have been a welcomed alternative to topical corticosteroids because their chronic use is not associated with skin barrier compromise or increasing percutaneous absorption. However, in January 2006, the US Food and Drug Administration (FDA) instituted a boxed warning for both TCIs based on a theoretical risk of malignancy (including lymphomas) that sparked an ongoing debate over the safety of these drugs. Since then, despite a number of epidemiological and clinical studies, no clear link between TCI use and lymphoma risk has been established. Yet, the boxed warning remains, leaving many physicians hesitant to prescribe TCIs and countless patients (including infants and children) exposed to other anti-inflammatory agents with proven adverse effects. This review will (1) present a historical overview of the basis for the boxed warning, (2) review and critically evaluate the evidence for lymphoma risk, (3) provide practical clinical and evidence-based advice on using TCIs in the management of AD, and (4) offer advice on addressing obstacles to patient access to these drugs.
2.1 Regulatory History of the Boxed Warning for TCIs
Tacrolimus ointment 0.03 and 0.1 % [Protopic®; owned and developed by Fujisawa (now Astellas)] and pimecrolimus cream 1 % (Elidel®; developed by Novartis, Meda acquired global rights to Elidel® in 2011 and immediately licensed North American rights to Valeant) are TCIs, which inhibit transcription and release of inflammatory cytokines and mediators from T cells . In December 2000, tacrolimus ointment was approved for “short-term and intermittent long-term therapy in the treatment of patients (≥2 years of age) with moderate to severe AD in whom the use of alternative, conventional therapies is deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or are intolerant of alternative, conventional therapies” . At that time, no efficacy or safety studies had been conducted with tacrolimus in infants, and the approved indication was limited to patients at least 2 years of age. One year later, in December 2001, pimecrolimus cream was approved with a similar indication for mild-to-moderate AD with similar warnings and contraindications based on pharmacological class . In contrast to tacrolimus, data demonstrating the safety and efficacy of pimecrolimus were available at the time of application for 436 infants who had participated in clinical trials. On the basis of the “disproportionately higher incidence of adverse events, particularly viral infections in infants,” seen in these trials, the approved indication was limited to patients 2 years of age and older. To further investigate the long-term safety of both drugs, the FDA requested post-approval commitments from both companies to establish pediatric registries [4, 5].
At the time of drug approval, the FDA requested that Astellas perform additional studies of topical tacrolimus including: a retrospective analysis to explore any demographic and disease factors possibly associated with persistently detectable blood concentrations ; bioavailability of 0.03 and 0.1 % ointments following long-term intermittent treatment of AD ; and pharmacokinetics of 0.03 % ointment in patients 2–5 years of age with moderate-to-severe AD .
Upon pimecrolimus cream approval, the FDA also requested that Novartis conduct two case-control epidemiological studies to assess the risk of non-melanoma  and melanoma skin cancers (protocol under FDA review) in adults; a controlled safety and efficacy study in HIV-positive patients; and a pregnancy registry. The last two requests were waived/fulfilled via labeling change or provision of additional preclinical data. In addition, Novartis initiated two ambitious long-term randomized clinical studies to assess the effects of pimecrolimus cream in infants as young as 3 months of age: a 6-year study (N = 1,091) designed to evaluate long-term safety and the impact of AD treatment on the progression of atopy; and a 5-year study (N = 2,418) designed to evaluate long-term safety including growth velocity and immune system development effects [9, 10, 11, 12, 13].
The PAC convened 15 months later in February 2005 to review the results of a newly completed oral carcinogenicity study conducted in monkeys (the results of which are discussed in detail in Sect. 3.1) as well as additional AERS malignancy reports. The concerns of the PAC were elevated in part by the manufacturers’ marketing efforts, escalating TCI sales, and a higher rate of off-label use. On the basis of the recommendation made at this meeting, the FDA issued a public health advisory in March 2005 and a requirement in January 2006 for revised labeling for both products to include a boxed warning (‘black box’) and medication guide (‘patient medi guide’) to address a theoretical risk of lymphoma and to emphasize that the safety of long-term continuous use and use in patients 2 years of age and younger had not been established [14, 15]. In addition, the indications were modified to specify that TCIs are “second-line [emphasis added] therapy for short-term and non-continuous chronic treatment…of [AD] in non-immunocompromised adults and children [≥2 years of age] who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable” [3, 16]. This was the first time that the FDA required that a boxed warning be issued on the basis of a theoretical risk rather than proven safety concerns.
At subsequent meetings held in March 2010 and May 2011, the PAC reviewed post-marketing surveillance (PMS) and epidemiological data for both drugs and found it to be inconclusive with regards to both long-term safety concerns and malignancy risk [17, 18]. At both meetings, the committee requested that the FDA continue to monitor the literature, AERS, and product registries and maintain the boxed warning until conclusive evidence was found . In light of these inconclusive findings, this re-examination of a possible link between TCI use and lymphoma was undertaken.
2.2 Response from the Public and the Medical Community
News coverage of the boxed warnings was widespread, with stories appearing in notable publications, including USA Today , Washington Post , BBC News , and Consumer Reports . The resulting patient concerns led some patients and caregivers to dispose of their TCIs and opt for other treatments or forgo treatment altogether. Law firms began posting websites dedicated to soliciting litigations against the makers of TCIs [23, 24, 25, 26, 27], further adding to the anxiety among patients and caregivers.
Members of the medical community criticized the FDA’s action and suggested that an unintended result was to jeopardize the chances of ever clarifying the risks due to decreased participation in clinical trials . Some argued that the FDA did not fairly weigh the data with respect to low systemic exposure seen in humans, lack of cancer adverse events in clinical studies, overall low rate of malignancy reports, and lack of evidence for systemic immune suppression with topical application of market formulations in preclinical studies. Critics also argued that the FDA overlooked the unmet medical need for these agents as an alternative to topical corticosteroids, especially for infants and patients with facial involvement [28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42]. Furthermore, some members of the medical community questioned the plausibility of a biological link between immunosuppression and the types of cancers observed [40, 41, 42]. On the other hand, the FDA did not rescind either drug’s approval or request the termination of any of the ongoing clinical trials for either of these drugs.
2.3 Consequences of the Boxed Warning
3 Summary of the Evidence for Lymphoma Risk
3.1 Preclinical Data
Relevant repeat-dose toxicity and carcinogenicity studies in animals as reviewed by the FDA (at approval)
Systemic immune suppression observed? (AUC; safety margina)
No relationship of tumor incidence was found
No relationship of tumor incidence was found
104-week oncogenicity of topical tacrolimus ointment (marketed formulation) in B6C3FI mice 
The increased incidence of pleomorphic and undifferentiated lymphomas are probably due to the established pharmacologic effect of tacrolimus, but the safety factor is sufficient that “human patients would not have a high risk”
(~180 ng·h/mL; tenfold)
• Topical tacrolimus ointment 0.1 % was associated with a statistically significant increase in the incidence of pleomorphic lymphoma (males and females) and undifferentiated lymphoma (females) mostly of B cell type
• No skin carcinomas were noted
13-week toxicity of topical pimecrolimus in ethanol in CD-1 mice
The increased incidence of pleomorphic lymphomas observed in this study may be related to the pharmacological action of and systemic exposure to pimecrolimus
Yes; assumed related to ethanol vehicle
(males: 643 ng·h/mL; 17-fold;
females: 675 ng·h/mL; 18-fold)
• Topical pimecrolimus 25 and 50 mg/kg/day were associated with lymphoproliferative changes, including malignancies
Oncogenicity of oral (gavage) pimecrolimus in CD-l mice for their life-span
The increased incidence of malignant lymphoma was most likely a consequence of systemic immunosuppression, but the safety factor is “adequate” for use in humans
(males: 2,260 ng·h/mL; 60-fold/females: 5,059 ng·h/mL; 133-fold)
• Oral pimecrolimus 45 mg/kg/day was associated with a statistically significant increase in the incidence of follicular center cell lymphoma, pleomorphic lymphoma, and combined lymphoma in both males and females
104-week oncogenicity of oral (gavage) pimecrolimus in Wistar rats (2 replicates)
The increased incidence of benign thymoma is a significant finding but may not be relevant to humans; the safety factor for females is “adequate” for use in humans, but not for males
(males: 42 ng·h/mL; 1.1-fold/females: 805 ng·h/mL; 21-fold)
• Oral pimecrolimus 5 mg/kg/day (males) and 10 mg/kg/day (males and females) were associated with a “biologically significant” increase in the incidence of benign thymoma
104-week carcinogenicity of topical pimecrolimus cream (marketed formulation) in Wistar ratsc
The increased incidence of follicular cell adenoma of the thyroid is a significant finding but may not be relevant to humans; the safety margin is not as great as noted in other carcinogenicity studies, but since the highest feasible dose was used, the study was considered adequate
Not clear; but no significant toxicity was noted
(57 ng·h/mL based on highest feasible dose; 1.5-fold)
• A statistically significant increase in the incidence of follicular cell adenoma in the thyroid in all topical pimecrolimus cream dose groups (0.2, 0.6, and 1.0 %) was noted in males onlyd
• A slight (non-significant) increase in benign thymoma was seen in males at all doses and in females at the 0.2 % dose levele
• Non-neoplastic minimal-to-moderate application site epithelial hyperplasia was noted for both pimecrolimus cream and vehicle; this was attributed to vehicle effects
• No lymphomas were noted
The most common forms of malignancy seen in transplant patients treated with systemic (oral or intravenous) tacrolimus for graph-versus-host prophylaxis are skin carcinomas and non-Hodgkin’s lymphomas (NHL) associated with Epstein–Barr virus infection, which may regress with treatment discontinuation . In order to determine if systemically administered oral pimecrolimus can act through a similar mechanism, a 39-week oral (gavage) toxicity study was conducted in monkeys. The results of this study, reviewed by the FDA in February 2005, confirmed that oral pimecrolimus, given at doses sufficient to result in systemic immune suppression (~30-fold greater than the maximal exposure in humans with topical application), can elicit lymphomas associated with Epstein–Barr-like primate viruses similar to oral tacrolimus . These results were cited as part of the basis for the boxed warning requirement for topical application [14, 50] despite the fact that administration was oral rather than topical and that evidence of systemic immune suppression was not detected following topical administration.
3.2 Epidemiological Data
The literature review considered at the March 2010 PAC meeting [51, 52] included conflicting data, summarized by Tennis et al. . In comparison to untreated AD patients, Hui et al.  reported an increased risk of T cell lymphoma among tacrolimus ointment users (hazard ratio [95 % CI]; 3.13 [1.41–6.94]), but not among pimecrolimus cream users [1.86 (0.71–4.87)]. On the other hand, Arellano et al.  found no association between TCI use (pimecrolimus cream or tacrolimus ointment) and lymphoma of any type (adjusted odds ratio [95 % CI]; 0.82 [0.42–1.61] and 0.79 [0.37–1.71], respectively) compared with untreated AD patients. Schneeweiss et al.  also report no significant increase in risk for lymphoma of any type (rate ratio [95 % CI]; pimecrolimus cream: 1.79 [0.92–3.48]; tacrolimus ointment: 1.97 [0.87–4.50], respectively) nor for cutaneous lymphomas (1.49 [0.36–6.24]; 2.53 [0.51–12.6], respectively) when TCI users were compared with untreated AD patients. As with all retrospective studies, each of these reports has significant limitations, including low numbers of pediatric patients, short duration, potential association between AD and lymphoma, no assessment by lymphoma subtype, exclusion of a lag period, and lack of case verification.
A full report of an additional long-term study was available for the May 2011 PAC meeting . This study found no evidence for increased risk of lymphoma of any type for the overall population (625,915 patients; adjusted odds ratio [95 % CI]; pimecrolimus cream: 0.76 [0.54–1.08]; tacrolimus ointment: 1.24 [0.80–1.91]) or among those patients younger than 20 years of age (396,069 patients; pimecrolimus cream: 0.64 [0.34–1.21]; tacrolimus ointment: 0.96 [0.38–2.45]) compared with untreated AD patients (patients were followed from 6 months to over 10 years). Among patients exposed to the highest cumulative dose of tacrolimus ointment (≥0.10 g), the risk of lymphoma was significantly increased (2.08 [1.24–3.49]); however, no association was evident for pimecrolimus cream. When T cell lymphomas were evaluated alone, they found an increased risk of T cell lymphoma among tacrolimus ointment users (4.95 [1.86–13.19]), which was dose-dependent (<0.03 g: 4.27 [0.24–75.49]; ≥0.03 to <0.06 g: 5.36 [0.78–37.05]; ≥0.06 to <0.10 g: 6.03 [1.31–27.70]; ≥0.10 g; 12.76 [3.35–48.68]). T cell lymphoma risk was not elevated among pimecrolimus cream users (0.85 [0.25–2.90]) and showed no dose-dependence. Dose-dependence results for T cell lymphoma should be interpreted with caution, however, because of the low number of cases in each category.
3.3 Clinical Databases
Actual number of malignancy and lymphoma (Hodgkin’s and Non-Hodgkin’s) reports in clinical databases compared with the expected number of reports in the general population (based on SEER )
4 Critical Evaluation of the Evidence
A number of generally confounding factors must be considered when evaluating the strength of the evidence that led to the FDA decision to apply the boxed warning—the difficulty in assessing the risk of rare events, possible confounding effects of disease state and severity, and a consideration of risks and benefits across a number of alternative therapies. Confounding factors specific to this examination include the relative importance of preclinical versus clinical data and the intrinsic properties of each of the compounds.
4.1 Inherent Difficulties in Assessing the Risk of Rare Events
Assessing risk based on spontaneous adverse event reports (such as AERS) is complicated because of variable under-reporting, indeterminate population size, and inconsistent data quality, especially for details on drug exposure and underlying diseases . Spontaneous reporting might be especially problematic for adverse events with long latency times. Adverse events are believed to be under-reported to the FDA by a factor of as much as 10 and the reporting rate changes for the same product over time, with new and highly publicized drugs susceptible to increased reporting rates.
4.2 Confounding Factors: Disease State and Severity
The interpretation of results of studies examining risk associated with TCI exposure alone may be challenging because of several confounding factors. Namely, that AD like psoriasis (another inflammatory skin disease) may be independently associated with a risk of developing lymphoma, which increases with severity [53, 67, 68, 69, 70, 71]. On the other hand, in some cases, cutaneous T cell lymphoma may be misdiagnosed as AD (and treated as such) owing to similar clinical signs and symptoms [29, 72, 73, 74]. In addition, patients receiving TCIs as second-line therapy or at higher doses may bias the patient population toward more severe disease and greater exposure, thereby also increasing the potential for misleading results.
4.3 Benefit–Risk Analysis: Considering Alternative Therapies
In order to properly weigh the risks and benefits of AD treatment, one must consider the benefits and adverse effects of all possible treatments. Topical corticosteroids (TCS) are the mainstay of treatment for AD flares. However, no TCSs are indicated for long-term (>4 weeks) use and few are approved for patients younger than 2 years of age  because of skin-thinning potential and rebound effects. TCIs, on the other hand, have low atrophogenic potential  and skin permeation (as discussed in Sect. 4.5.1) and can be used for long periods, even on sensitive skin areas, without risk of developing tachyphylaxis [77, 78, 79, 80, 81, 82, 83, 84, 85, 86].
There are no preclinical carcinogenicity studies of TCS due to rapid toxicity in mice and rats, although, as an immune suppressant, there is a plausible link. In fact, other alternative anti-inflammatory AD treatments (i.e., oral corticosteroids, oral immunosuppressives, and phototherapy) all carry a risk of cancer [42, 71], and malignancy risk with TCS is unclear [56, 87, 88, 89].
4.4 Sufficient Evidence for TCI Boxed Warning?
According to FDA guidance, boxed warnings are ordinarily applied when (a) there is an adverse reaction so serious in proportion to the potential benefit from the drug (e.g., fatal, life-threatening, or permanently disabling) that it is essential that it be considered when assessing the benefit–risk ratio of prescribing the drug; (b) there is a serious adverse reaction that can be prevented or reduced in frequency or severity by appropriate use of the drug (e.g., patient selection, careful monitoring, avoiding use in a specific clinical situation); or (c) the FDA approved the drug with restrictions to ensure safe use . According to the guidance, a boxed warning can also be used to highlight information that is considered especially important to the prescriber (e.g., reduced effectiveness in certain patient populations). Boxed warnings are most often based on observed serious adverse reactions (i.e., clinical data) or, in some cases, based on anticipated adverse reactions [i.e., an expected adverse reaction based on pharmacologic action of the drug (preclinical data)]. Beach et al.  found that over 80 % of boxed warnings (in the 1995 Physicians’ Desk Reference) were based on clinical data including adverse event reports obtained through clinical trials and spontaneous reports. Only 9 % of warnings were based on ‘other’ evidence.
The boxed warning for TCIs was implemented despite the fact that “a causal relationship has not been established” [3, 16]. While no specific risks have been identified, the label indicates that “long-term safety of topical calcineurin inhibitors has not been established…[and] rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with [TCIs]” [3, 16]. In contrast, the boxed warning for long-acting β-agonists for childhood asthma is based on data from large placebo-controlled trials that showed an increase in asthma-related deaths .
There is some precedent for removing a boxed warning based on differences in systemic exposure between oral and topical formulations and/or new clinical data [93, 94, 95]. Given the inconclusive nature of prior evidence, the clinical value of TCIs, and the negative impact of limiting patients’ access to TCIs, significant weight should be given to more recent epidemiological and clinical data when considering the ongoing need for the boxed warning.
4.5 Justification for a Class Labeling?
The FDA applies pharmacological classes to drugs in order to help prescribers avoid duplicative therapy and drug interactions. In order to maintain consistency, the agency considers applying warnings, contraindications, and boxed warnings to all members of a pharmacological class; however, it does allow for these to be applied to a single member of a class if the benefit–risk ratio is shown to apply to only one member . Low systemic exposure with TCIs and striking differences between pimecrolimus cream and tacrolimus ointment in terms of pharmacology and clinical development programs might justify reconsideration of class labeling and/or warnings.
4.5.1 Low Systemic Exposure
Many studies with both pimecrolimus cream and tacrolimus ointment have shown systemic exposure to be low after topical treatment in AD patients as young as 3 months of age [7, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106]. In a head-to-head comparison study, the highest blood concentrations detected in adults with moderate-to-severe AD were 1.51 ng/mL in the pimecrolimus cream group and 2.39 ng/mL in the tacrolimus ointment group, both of which are substantially below target trough concentrations for systemic immunosuppression for tacrolimus (5–20 ng/mL) in transplant patients . In infants, blood concentrations are similar to those seen in adults with no evidence of accumulation for up to 1 year [101, 102, 103, 104, 105, 106]. The highest blood concentrations reported for infants with pimecrolimus cream 1 % range from 1.8 to 4.14 ng/mL [101, 102, 103, 104, 105] and the average maximum concentration with tacrolimus ointment 0.03 % was 3 % of that observed in pediatric liver-transplant patients receiving oral tacrolimus .
In vitro skin penetration (into) for each compound is approximately equal, but skin permeation (through) is greater for tacrolimus ointment than pimecrolimus cream [108, 109]. When comparing relative permeation in normal versus inflamed or corticosteroid-pretreated skin, both compounds permeated inflamed and corticosteroid-pretreated skin to a greater extent (up to a factor of 6 times greater than normal skin) . Thus, exposure to TCIs is self-limiting—as skin barrier function is restored, exposure decreases. There is also the argument that pediatric patients may have greater systemic exposure because of their greater body surface area to weight ratio. In the head-to-head trial, when blood concentrations after tacrolimus ointment application were analyzed by total body surface area (TBSA) affected by AD, they were detectable in more patients as TBSA affected by AD increased .
4.5.2 Differences in Pharmacology
Unlike tacrolimus, which was originally developed for its antirejection activity, pimecrolimus was developed specifically to target inflammatory skin diseases on the basis of its pharmacology . After oral administration in rats, skin concentrations of pimecrolimus were consistently greater (twofold) than that of tacrolimus whereas in other tissues tested (blood, lymph nodes), concentrations of tacrolimus were greater (6-fold and 50-fold, respectively) . In several animal models, pimecrolimus demonstrated much lower immunosuppressive potential than tacrolimus [1, 110, 112, 113, 114, 115].
4.5.3 Differences in Clinical Programs
Pimecrolimus cream and tacrolimus ointment clinical development programs in atopic dermatitis
5 Implications for Daily Practice
5.1 Increased Burden on Medical Providers and their Patients
Practicing physicians and their office staff bear the bulk of administrative burden generated by the boxed warning, while patients assume additional personal and financial burden. In response to the warning, third-party payers restricted off-label access to TCIs for children with conditions other than TCS-failing AD, and for all infants. Most third-party payers require time-consuming prior authorization for all TCI prescriptions. In many states, Medicaid-insured children have no access to these corticosteroid-sparing medications  based on disease and age-specific labeling, amounting to discriminatory denials. Some physicians may be hesitant to prescribe TCIs because of a higher perceived medicolegal liability .
5.2 Consequences of Inaccurate Diagnosis
Cutaneous T cell lymphoma is a chronic condition with insidious onset that may be misdiagnosed as AD, complicating assessment of a true lymphoma risk associated with TCIs.
5.3 Consequences of Inadequate Treatment
Active AD can have significant negative impact on quality of life for patients and their caregivers. Adequate treatment has been shown to significantly improve quality of life and patient satisfaction [121, 122]. In addition, early disease control may slow or prevent the “atopic march” to subsequent allergic rhinitis, food allergy, and asthma . Suboptimal management of AD leads to more frequent flares and greater likelihood of exposure to medications like systemic corticosteroids, cyclosporine, or other immunosuppressants with higher toxicity risks . And in contrast to frequent application of TCS, daily maintenance therapy with TCIs does not interfere with skin barrier integrity or enhance percutaneous absorption. Recommendations to limit exposure to topical therapy with TCIs places disproportionate importance on theoretical drug-related risks compared with well-established risks of chronic skin disease.
In addition, the costs of inadequately treated AD are substantial [124, 125, 126, 127]. Dermatology is among the most difficult subspecialty to gain access to for publically insured children . The frequency of emergency department (ED) visits for AD observed in one Midwest urban hospital suggests restricted access to outpatient care and suboptimal maintenance treatment, adding significant cost . Emergency medicine providers receive limited training in the management of dermatological issues [119, 129]. Furthermore, prescription assistance programs (including the Allergy and Asthma Foundation, the Health Well Foundation, and the Chronic Disease Fund) do not include AD as an eligible indication.
5.4 Optimal Use of TCIs
As a corticosteroid-sparing agent: Reducing the risks of chronic TCS exposure is important, especially in children treated with intranasal, inhaled, or systemic corticosteroids for other atopic diseases such as asthma or allergic rhinitis. The corticosteroid-sparing effect of pimecrolimus cream has been demonstrated in clinical trials [77, 78, 79, 130, 131, 132, 133, 134]. A reduced number of flares and prolonged time-to-flare quantified in tacrolimus ointment clinical trials also supports a corticosteroid-sparing effect [135, 136, 137, 138, 139, 140].
To treat face and skin fold disease: Skin atrophy, perioral dermatitis, and increased percutaneous absorption are TCS risks prompting greatest concern in patients with inflammatory skin disease involving sensitive skin areas on the face, eyelids, and diaper area. TCIs are well suited for use in these areas due to low acnegenic and atrophogenic potential [76, 78, 83, 131, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152].
To simplify treatment regimens: Risks associated with TCS use are highest with more potent products, especially when applied to sensitive skin areas. To minimize these risks, a popular approach is to recommend a two-drug treatment regimen using a lower potency TCS on the face and a higher potency product on the body. Patients are often confused about the appropriate drug to use on the affected sites, and monitoring the optimal quantity used can also be complicated. Maintenance treatment with a TCI requires use of only one product on all affected sites. This not only simplifies treatment for the patient, but also allows easier monitoring of drug quantity used over time.
For children who require daily treatment: Safety of TCS has been studied for durations of no longer than 4 weeks for a limited number of products. In contrast, safety of TCIs for durations of up to 1 year has been documented in several prospective trials and registries [83, 84, 85, 86].
In patients who are TCS intolerant or dependent: Well-described but under-recognized complications of long-term use of TCS include delayed-type hypersensitivity reactions, and rebound erythroderma. Neither pimecrolimus cream nor tacrolimus ointment carry these risks [150, 151, 152, 153].
In patients with confirmed or suspected skin infection: ‘In cognito’ TCS-associated skin infections are another complication that has been well-described but underappreciated . The proposed mechanism of action is via dendritic cells and antigen presentation . In contrast, TCIs do not affect the differentiation, maturation, or function of dendritic cells [156, 157, 158, 159, 160, 161, 162]. Clinical trials have not identified an increased incidence of skin infection for either TCI [82, 163, 164].
5.5 Effective Communication with Patient About the Benefit–Risk Ratio
The risk of lymphoma and other cancers is no higher than what you see in the general population.
TCI molecules are about twice the size of corticosteroids, which makes it more difficult for them to permeate the skin and cause systemic adverse effects.
All drugs, including TCIs and corticosteroids, have risks and benefits.
The American Academy of Dermatology (AAD) and other professional organizations do not support the boxed warning.
Pharmacists and other healthcare professionals may provide you with information that conflicts with what we have discussed.
As your physician, I have carefully weighed the risks and benefits of prescribing a TCI and feel that this drug is well suited to manage your skin condition.
The TCIs were a welcome therapeutic option for the management of AD when they were approved over 10 years ago, and they remain the only approved treatment for long-term use in children 2 years of age and older. Physicians quickly adopted the TCIs as a corticosteroid-sparing adjunct to topical corticosteroids. Despite the utility of TCIs, in January 2006, the FDA implemented a boxed warning regarding the safety of long-term use and a possible risk of lymphoma and limited the indication to “second-line therapy for the short-term and noncontinuous chronic treatment of (mild-to-moderate or moderate-to-severe AD) in nonimmunocompromised adults and children (≥2 years of age) who have failed to respond adequately to other topical prescription treatments for (AD), or when those treatments are not advisable” [3, 16]. This had a significant impact on physician prescribing patterns and patient access to these medications, leading to decreased disease control and quality of life for patients and their families. Many members of the medical community criticized the actions of the FDA. They questioned the validity of the boxed warning in large part because no definitive human clinical trial data has demonstrated an increased risk of malignancy with TCI exposure. In addition, several epidemiological studies have shown no association between TCI use and lymphoma risk in clinical practice, and the incidences of malignancy and lymphoma in clinical databases are below that of the general population. In addition, a possible association between AD itself and malignancy further erodes the basis for the warning. In order to provide patients with optimal care, physicians must have strategies for mitigating the impact of the boxed warning on the quality and costs of AD management. These include using TCIs appropriately as corticosteroid-sparing agents and proactively communicating the relative risks and benefits of TCIs to patients and their caregivers.
This manuscript was developed independent of any funding source. Dr. Siegfried is a full-time employee of Saint Louis University. Dr. Hebert is a full-time employee of the University of Texas Medical School at Houston. Drs. Siegfried and Hebert provided clinical perspective, guided the overall direction and content of the manuscript, and approved the final version for submission; neither received additional financial support for this work. Jennifer Jaworski, a full-time employee of Prescott Medical Communications Group (Chicago, IL, USA), drafted the manuscript at their direction and performed background research and data calculations with financial support from Valeant Pharmaceuticals North America LLC (Bridgewater, NJ, USA).
Dr. Siegfried has participated in contract research with Astellas Pharma US (prior to 2001) and Novartis Pharmaceuticals Corporation (prior to 2004); financial compensation for this work was paid directly to her employer. She received travel expenses related to presentation of some of this contract research from Valeant Pharmaceuticals North America LLC (in 2012). She has received consulting fees from Novartis Pharmaceuticals Corporation (prior to 2006).
Dr. Hebert has received consulting fees, been a member of speakers’ bureaus, and/or served on advisory boards for Astellas Pharma US, Novartis Pharmaceutical Corporation (prior to 2008), and Valeant Pharmaceuticals North America LLC. In addition, she has participated in contract research with Astellas Pharma US and Novartis Pharmaceuticals Corporation; financial compensation for this work was paid directly to her employer. She has also served as a member of data safety monitoring boards for Valeant Pharmaceuticals North America LLC and Novartis Pharmaceuticals Corporation.
- 2.Protopic® (tacrolimus) ointment 0.03% and ointment 0.1% [US prescribing information]. Deerfield: Fujisawa Healthcare, Inc. 2000.Google Scholar
- 3.Elidel® (pimecrolimus) cream 1% [US prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation. 2010.Google Scholar
- 4.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Protopic NDA 50-777 approval letter. December 8, 2000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50777_Protopic_Approv.pdf. Accessed 23 Jan 2012.
- 5.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 approval letter. December 13, 2001. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-302_ELIDEL_Approv.pdf. Accessed 23 Jan 2012.
- 6.Data on file, Astellas Pharma US, 2012.Google Scholar
- 10.Hanifin JM, Paller AS, Eichenfield LF, et al. The demographic profile of a large population of infants with atopic dermatitis: a longitudinal study on development of asthma and allergies [abstract]. J Am Acad Dermatol. 2007;56(Suppl 2):AB68 (Abstract P703).Google Scholar
- 11.Paller AS, Figliomeni ML, Hultsch T, et al. Efficacy and safety of pimecrolimus cream 1% in 1088 infants with atopic dermatitis: Results of the three year double-blind, vehicle controlled phase of the study of the atopic march [abstract]. Dermatitis. 2008;19(5):294–5.Google Scholar
- 12.Bishop M, Poulin Y, Qaqundah P, et al. A 5-year randomized study to investigate the safety of pimecrolimus cream 1% in the treatment of mild-to-moderate atopic dermatitis in infants: clinical safety [abstract]. J Am Acad Dermatol. 2011;64(2 Suppl 1):AB56 (Abstract P1301).Google Scholar
- 13.Poulin Y, Bishop M, Johnson A, et al. A 5-year randomized study to investigate the safety of pimecrolimus cream 1% in the treatment of mild-to-moderate atopic dermatitis in infants: immunological parameters [abstract]. J Am Acad Dermatol. 2011;64(2 Suppl 1):AB58 (Abstract P1310).Google Scholar
- 14.Briefing memorandum from Dianne Murphy, Director, Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration. February 15th, 2005 Pediatric Advisory Committee meeting on the possible risk of cancer from use of the topical immunosuppressants, February 7, 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2_01_01_%20Briefing%20Memo.pdf. Accessed 23 Jan 2012.
- 15.US Food & Drug Administration (FDA). FDA approves updated labeling with boxed warning and medication guide for two eczema drugs, Elidel and Protopic [media release]. 2006 January 19 [online]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm153941.htm. Accessed 18 Jan 2012.
- 16.Protopic® (tacrolimus) ointment 0.03% and ointment 0.1% [US prescribing information]. Deerfield: Astellas Pharma US, Inc. 2011.Google Scholar
- 17.Minutes of the Pediatric Advisory Committee meeting. March 22, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM208036.pdf. Accessed 23 Jan 2012.
- 18.Minutes of the Pediatric Advisory Committee meeting. May 16, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM261384.pdf. Accessed 23 Jan 2012.
- 19.FDA cautions doctors on eczema treatment. Associated Press. USA Today. 2005 Mar 10.Google Scholar
- 20.Stein R. FDA considers warnings for eczema creams. Washington Post. 2005 Feb 12;Sect A: A.09.Google Scholar
- 21.Cancer warning over eczema creams. BBC News. 2005 Mar 11.Google Scholar
- 22.New warnings, risks, or restrictions for three skin drugs. ConsumerReports.org. 2005 Mar 15.Google Scholar
- 23.Elidel Lawsuits, Litigation & Lawyers—What you should know [online]. FreeAdvice Staff. http://injury-law.freeadvice.com/injury-law/drug-toxic_chemicals/elidel-lawsuit.htm. Accessed 8 Mar 2012.
- 24.Elidel and skin cancer [online]. LawyersandSettlements.com. http://www.lawyersandsettlements.com/case/elidel.html. Accessed 8 Mar 2012.
- 25.Elidel and the FDA ‘black box’ warning [online]. Awko Law. http://www.awkolaw.com/elidel/. Accessed 8 Mar 2012.
- 26.Eczema drugs Elidel and Protopic have been shown to cause cancer [online]. Weitz & Luxenberg P.C. http://www.weitzlux.com/eczema-elidel-protopic-cancer_218024.html. Accessed 8 Mar 2012.
- 27.Elidel law suit [online]. Oshman & Mirisola, LLP. http://www.oshmanlaw.com/pharmaceutical_litigation/elidel.html. Accessed 8 Mar 2012.
- 28.Siegfried E, Silverman RA, Mancini AJ. ‘Black box’ warning ill-advised for eczema drugs. Dermatol Times. 2006;27(3):6.Google Scholar
- 31.Thaci D, Salgo R. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update. Acta Dermatovenerol Alp Panonica Adriat. 2007;16(2):58, 60–62.Google Scholar
- 32.Orlow S. Calcineurin inhibitors and black boxes. Pediatric News. Mar 2006:24.Google Scholar
- 35.Canadian Dermatology Association (CDA). Position statement on topical calcineurin inhibitors [media release]. 2005 April [online]. http://www.dermatology.ca/media/position_statement/position_topical_calcineurin_inhibitors.html. Accessed 24 Jan 2012.
- 36.American Academy of Dermatology (AAD). American Academy of Dermatology issues statement in response to FDA decision related to two eczema medications [media release]. 2005 March 20 [online]. http://www.thefreelibrary.com/American+Academy+of+Dermatology+Issues+Statement+In+Response+to+FDA-a0130070456. Accessed 5 Apr 2012.
- 37.Fleischer AB. Show me the signal, FDA. Skin Allergy News. May 2005:10.Google Scholar
- 39.Lebwohl M. Labeling changes for the topical calcineurin inhibitors: an expert interview with Mark Lebwohl, MD. Medscape Dermatol. 2006;7(1).Google Scholar
- 41.Eichenfield L. Topical pimecrolimus, tacrolimus, and the risk for cancer: an expert interview with Lawrence Eichenfield, MD. Medscape Dermatol. 2005;6(1).Google Scholar
- 44.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Protopic NDA 50-777 pharmacology review. June 19, 2000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50777_protopic.cfm. Accessed 19 Mar 2012.
- 45.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 pharmacology review. November 6, 2001. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-302_Elidel.cfm. Accessed 19 Mar 2012.
- 46.Pediatric Advisory Committee presentation from Barbara Hill, Division of Dermatologic and Dental Drug Products, FDA Center for Drug Evaluation and Research. Topical immunosuppressants (calcineurin inhibitors)—animal toxicology. February 15, 2005. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4089s2_01_06_Hill.ppt. Accessed 2 Apr 2012.
- 47.Prograf® (tacrolimus) capsules and injection [US prescribing information]. Deerfield: Astellas Pharma US, Inc. 2011.Google Scholar
- 48.Sandimmune® (cyclosporine) soft gelatin capsules, oral solution, and injection [US prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation. 2010.Google Scholar
- 49.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 pharmacokinetics/toxicokinetics review. 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2_01_07_Tox%20Review%20Redacted.pdf. Accessed 2 Apr 2012.
- 50.Minutes of the Pediatric Advisory Committee meeting. February 15, 2005. http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4089m1_Minutes.pdf. Accessed 4 Apr 2012.
- 51.Briefing document from Angelika Manthripragada, Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Calcineurin inhibitor pediatric literature review, September 23, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255139.pdf. Accessed 23 Jan 2012.
- 52.Briefing document from Angelika Manthripragada, Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Addendum: Update on calcineurin inhibitor pediatric literature review, May 10, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255140.pdf. Accessed 23 Jan 2012.
- 57.Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute [online]. http://seer.cancer.gov/faststats. Accessed 8 Jun 2012.
- 59.Pediatric Advisory Committee presentation from Seth J Orlow, Chairman & Weinberg Professor of Pediatric Dermatology, Director, Center of Excellence in Cancers of the Skin, New York University School of Medicine. Melanocytic lesions in children and adolescents, March 22, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM207878.pdf. Accessed 3 Apr 2012.
- 60.Pediatric Advisory Committee presentation from M Joyce Rico, Vice President, Medical Affairs, Astellas Pharma Global Development. Protopic® (tacrolimus) Ointment, February 15, 2005. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4089s2_03_01_Fujsawa%20FDA%20Feb%2015.ppt. Accessed 31 May 2012.
- 61.Ohtsuki M, Ohara H, Santos V, et al. Safety profiles of two large cohort studies of tacrolimus ointment for the treatment of atopic dermatitis: a prospective pediatric longitudinal evaluation study (APPLES) and japanese long-term safety study (J-LSS) [abstract]. In: Proceedings of the 22nd World Congress of Dermatology Meeting; 2011; Seoul, Korea, Poster P0327.Google Scholar
- 62.Briefing document from Namita Kothary, Safety Evaluator, Division of Pharmacovigilance I, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Update on Malignancies in Children, April 4, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255145.pdf. Accessed 23 Jan 2012.
- 63.Data on file, Valeant Pharmaceuticals North America LLC, 2012.Google Scholar
- 64.Briefing book from Fujisawa Healthcare, Inc. Discussion topic: risk evaluation, labeling, risk communication, and dissemination of information on potential cancer risk among pediatric patients treated for atopic dermatitis with topical dermatological immunosuppressants, January 27, 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2_02_02_Protopic%20Fujisawa%20briefing.pdf. Accessed 6 Aug 2012.
- 65.Briefing document from Patty Greene, Drug Use Data Analyst, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. BPCA drug use review: comparison of Elidel® cream and Protopic® ointment utilization trends following 2006 labeling changes, July 17, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM204723.pdf. Accessed 2 Apr 2012.
- 74.Elmer KB, George RM. Cutaneous T-cell lymphoma presenting as benign dermatoses. Am Fam Phys. 1999;59(10):2809–13.Google Scholar
- 75.National Eczema Association (NEA). Topical corticosteroids: Myths & facts [online]. http://www.nationaleczema.org/eczema-treatments/topical-corticosteroids Accessed 2 Apr 2012.
- 87.Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol. 2009;123(5):1111–6, 116 e1–13.Google Scholar
- 89.Arana A, Wentworth CW, Rivero E, et al. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids and/or topical calcineurin inhibitors [abstract]. J Am Acad Dermatol. 2011;64(2 Suppl 1):AB3 (Abstract P203).Google Scholar
- 90.Guidance for Industry. Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products – content and format. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER). October 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075096.pdf. Accessed 19 Mar 2012.
- 92.Advair Diskus 100/50, 250/50, and 500/50 (fluticasone propionate 100/250/500 mcg and salmeterol 50 mcg inhalation powder) [US prescribing information]. Research Triangle Park: GlaxoSmithKline. 2011.Google Scholar
- 93.Metronidazole tablets USP [US prescribing information]. Corona: Watson Pharma, Inc. 2010.Google Scholar
- 94.Metronidazole gel 0.75% USP [US prescribing information]. Hawthorne: Taro Pharmaceuticals USA, Inc. 2011.Google Scholar
- 95.US Food and Drug Administration (FDA). FDA modifies boxed warning for pulmonary arterial hypertension drug Letairis [media release]. 2011 March 4, [online]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2011/ucm245848.htm. Accessed 21 June 2012.
- 111.Schweitzer A, Figueiredo J, Zehender H, et al. Pimecrolimus (SDZ ASM 981) has higher affinity for the skin than tacrolimus (FK 506)—a tissue distribution study in rats [abstract]. J Eur Acad Dermatol Venereol. 2002;16(Suppl 1):257 (Abstract P24-27).Google Scholar
- 114.Meingassner J, Di Padova F, Hiestand P, et al. Pimecrolimus (Elidel®,SDZ ASM 981): highly effective in animal models of skin inflammation but low activity in models of immunosuppression [abstract]. J Eur Acad Dermatol Venereol. 2001;15(Suppl 2):214 (Abstract P20-25).Google Scholar
- 115.Meingassner J, Hiestand P, Bigout M, et al. SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506 [abstract]. J Invest Dermatol. 2001;117(2):532 (Abstract 858).Google Scholar
- 116.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Protopic NDA 50-777 medical review. June 19, 2000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50777_protopic.cfm. Accessed 23 Jan 2012.
- 117.Pediatric Advisory Committee presentation from Joyce Rico, Vice President, Medical Affairs, Astellas Pharma Global Development. Topical tacrolimus ointment (Protopic®), May 16, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM261387.pdf. Accessed 3 Apr 2012.
- 118.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 medical review. November 6, 2001. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-302_Elidel.cfm. Accessed 5 Apr 2012.
- 119.Prodanovic E, Siegfried E, Peter J. Number and cost analysis of ed admissions for atopic dermatitis [abstract]. Caribbean Dermatology Symposium; 2010 Jan 19–23; San Juan, Puerto Rico.Google Scholar
- 120.AMA House of Delegates Health and Ethics Policies. Patient access to treatments prescribed by their physicians. H-120.988 2012. https://ssl3.ama-assn.org/apps/ecomm/PolicyFinderForm.pl?site=www.ama-assn.org&uri=/ama1/pub/upload/mm/PolicyFinder/policyfiles/HnE/H-120.988.HTM. Accessed 23 Jan 2012.
- 129.Wang E, Lim BL, Than KY. Dermatological conditions presenting at an emergency department in Singapore. Singap Med J. 2009;50(9):881–4.Google Scholar
- 135.Doss N, Kamoun MR, Dubertret L, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol. 2010;21(2 Pt 1):321–9.PubMedCrossRefGoogle Scholar
- 138.Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008;58(6):990–9.PubMedCrossRefGoogle Scholar
- 153.Leung DY, Hanifin JM, Pariser DM, et al. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. Br J Dermatol. 2009;161(2):435–43.PubMedCrossRefGoogle Scholar
- 158.Kwiek B, Peng WM, Allam JP, et al. Tacrolimus and TGF-beta act synergistically on the generation of Langerhans cells. J Allergy Clin Immunol. 2008;122(1):126–32, 132 e1.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. The exclusive right to any commercial use of the article is with Springer.